2023 World Conference on Lung Cancer (Posters)-P1.21. Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer

P1.21. Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This presentation at WCLC 2023 discusses the quantitative assessment of OX40L and its association with the sensitivity to front-line pembrolizumab in non-small-cell lung cancer (NSCLC) patients. The study aimed to uncover spatially resolved protein markers associated with a response to PD-1 axis inhibition in NSCLC patients who expressed high levels of PD-L1.<br /><br />The researchers collected tumor samples from 144 NSCLC patients treated with pembrolizumab and used the GeoMx Digital Spatial Profiling system to analyze the expression of 36 proteins. They focused the analysis on patients with an ECOG score of 0-1. OX40L expressed in the tumor compartment was found to be consistently associated with prolonged progression-free survival (PFS) in this cohort, independent of PD-L1 levels. OX40L expression correlated modestly with PD-L1 levels.<br /><br />The study found that there was limited expression of OX40L in the tumor microenvironment, with only about 20% of NSCLCs showing prominent levels of expression. OX40L expression was detected both in tumor cells and immune cells, without significant quantitative differences between both compartments. Patients with high OX40L expression in the tumor compartment had longer PFS.<br /><br />The findings suggest that OX40L expressed by tumor cells can be a marker associated with sensitivity to PD-1 axis blockade in treatment-naïve NSCLC patients with high PD-L1 expression. OX40L expression seems to be independent of PD-L1 expression at the tumor compartment level. The results support the use of therapeutic modulation of the OX40/OX40L axis combined with PD-1 axis inhibition in this subgroup of patients.<br /><br />Overall, this study identifies OX40L as a potential biomarker for predicting the response to pembrolizumab in NSCLC patients and highlights the importance of spatial profiling in understanding immuno-oncology biomarkers.

Asset Subtitle

Javier Baena

Meta Tag

Speaker Javier Baena

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

WCLC 2023

OX40L

sensitivity

pembrolizumab

NSCLC patients

PD-L1 expression

tumor samples

protein markers

spatial profiling

immuno-oncology biomarkers